Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

Original reporting
Published Nov 5, 2026, 7:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

Earnings beat and higher targets are likely to drive short‑term buying interest.

02

Market read

ZBH's earnings beat and analyst upgrades create a bullish catalyst for the stock and may influence the medical device sector.

03

What to watch

Potential supply‑chain or regulatory risks in the knee product line could dampen momentum.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

The article summarizes analyst price‑target revisions and ZBH's Q3 earnings, highlighting revenue growth and product segment performance.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Truist raised its price target on Zimmer Biomet to $114 and reported Q3 earnings that beat expectations, with revenue of $2.06B and EPS of $1.90.

Expected impact

likely upward pressure as investors price in higher target and earnings beat

Evidence & confidence

Multiple analysts raised targets and the company posted better-than-expected results, indicating improved fundamentals.

Market effects

Positive earnings and target upgrades may lift the broader medical device sector.

U.S. healthcare stocks could see modest gains.

Limited to U.S. equities; no direct global impact.

Counterpoint

If the knee segment weakness persists, the upside may be limited despite the upgrades.

Key entities

  • Zimmer Biomet Holdings Inc.

    Medical device maker reporting Q3 results.

  • Truist Securities

    Raised price target to $114.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.

$ZBHHighAI 8/10

Zimmer raises sales forecast despite slower knee business

Zimmer Biomet reported Q3 sales of $2.06B, up 3.1% YoY, with knee sales down 3.1% but hip sales up 6%. The company raised its 2026 revenue growth forecast to 4.4-4.9%. CEO Ivan Tornos attributed knee sales decline to commercial execution and market competition, not a broader slowdown, according to the company. Analysts, however, suggest market-related weakness. Zimmer plans to file an FDA application for a new surgical robot, acquired via Monogram Technologies, expecting a 2027 launch.